The Co-occurrence of early onset Parkinson disease and 22q11.2 deletion syndrome

American Journal of Medical Genetics, Part A

Volumn 149, Issue 3, 2009, Pages 525-528

  Zaleski, Christina ^a   Bassett, Anne S ^b,c   Tam, Karen ^d   Shugar, Andrea L ^d   Chow, Eva W C ^b,c   McPherson, Elizabeth ^a  

^a MARSHFIELD CLINIC   (United States)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA PLUS LEVODOPA; DOMPERIDONE; ENTACAPONE; ESCITALOPRAM; LEVODOPA; MIRTAZAPINE; PAROXETINE; QUETIAPINE; ROPINIROLE; TRAZODONE; ZOPICLONE;

ADULT; BALANCE DISORDER; BODY POSTURE; BRADYKINESIA; CASE REPORT; CHROMOSOME ANALYSIS; COORDINATION DISORDER; DEPRESSION; DIGEORGE SYNDROME; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DYSPHAGIA; EATING DISORDER; FACE DYSMORPHIA; GAIT DISORDER; HUMAN; HYPOPARATHYROIDISM; LEARNING DISORDER; LETTER; MALE; MEMORY DISORDER; MENTAL INSTABILITY; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; PARKINSON DISEASE; PRIORITY JOURNAL; SLEEP DISORDER; SPEECH DISORDER; SUICIDE ATTEMPT; TREMOR;

ADULT; AGE OF ONSET; CHROMOSOMES, HUMAN, PAIR 22; DIGEORGE SYNDROME; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 61749100480     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.32650     Document Type: Letter

References (23)

1. Bassett AS, Chow EW. 2008. Schizophrenia and 22q11.2 deletion syndrome. Curr Psychiatry Rep 10:148-157.
2. Bassett AS, Chow EW, Husted J, Weksberg R, Caluseriu O, Webb GD, Gatzoulis MA. 2005. Clinical features of 78 adults with 22q11 deletion syndrome. Am J Med Genet Part A 138A:307-313.
3. Bassett AS, Caluseriu O, Weksberg R, Young D, Chow EW. 2007. Catechol-O-methyl transferase and expression of schizophrenia in 73 adults with 22q11 deletion syndrome. Biol Psychiatry 61:1135-1140.
4. Bialecka M, Drozdzik M, Klodowska-Duda G, Honczarenko K, Gawronska-Szklarz B, Opala G, Stankiewicz J. 2004. The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease. Acta Neurol Scand 110:260-266.
5. Bialecka M, Drozdzik M, Honczarenko K, Gawronska-Szklarz B, Stankiewicz J, Dabrowska E, Kubisiak M, Klodowska-Duda G, Opala G. 2005. Catechol-O-methyltransferase and monoamine oxidase B genes and susceptibility to sporadic Parkinson's disease in a Polish population. Eur Neurol 53:68-73.
6. Bodis-Wollner I. 2003. Neuropsychological and perceptual defects in Parkinson's disease. Parkinsonism Relat Disord 9:S83-S89.
7. Botto LD, May K, Fernhoff PM, Correa A, Coleman K, Rasmussen SA, Merritt RK, O'Leary LA, Wong LY, Elixson EM, Mahle WT, Campbell RM. 2003. A population-based study of the 22q11.2 deletion: Phenotype, incidence, and contribution to major birth defects in the population. Pediatrics 112:101-107.
8. Chow EW, Watson M, Young DA, Bassett AS. 2006. Neurocognitive profile in 22q11 deletion syndrome and schizophrenia. Schizophr Res 87:270-278.
9. Elbaz A, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, Schaid DJ, Rocca WA. 2002. Risk tables for parkinsonism and Parkinson's disease. J Clin Epidemiol 55:25-31.
10. Foltynie T, Goldberg TE, Lewis SG, Blackwell AD, Kolachana BS, Weinberger DR, Robbins TW, Barker RA. 2004. Planning ability in Parkinson's disease is influenced by the COMT val158met polymorphism. Mov Disord 19:885-891.
11. Ishihara L, Brayne C. 2006. What is the evidence for a premorbid parkinsonian personality: A systematic review. Mov Disord 21:1006-1072.
12. Kaasinen V, Nurmi E, Bruck A, Eskola O, Bergman J, Solin O, Rinne JO. 2001. Increased frontal [(18)F]fluorodopa uptake in early Parkinson's disease: Sex differences in the prefrontal cortex. Brain 124:1125-1130.
13. Krahn LE, Maraganore DM, Michels VV. 1998. Childhood-onset schizophrenia associated with parkinsonism in a patient with a microdeletion of chromosome 22. Mayo Clin Proc 73:956-959.
14. Lynch DR, McDonald-McGinn DM, Zackei EH, Emanuel BS, Driscoll DA, Whitaker LA, Fishbeck KH. 1995. Cerebellar atrophy in a patient with velocardiofacial syndrome. J Med Genet 32:561-563.
15. Oskarsdottir S, Vujic M, Fasth A. 2004. Incidence and prevalence of the 22q11 deletion syndrome: Apopulation-based study in Western Sweden. Arch Dis Child 89:148-151.
16. Pycock CJ, Carter CJ, Kerwin RW. 1980. Effect of 6-hydroxydopamine lesions of the medial prefrontal cortex on neurotransmitter systems in subcortical sites in the rat. J Neurochem 34:91-99.
17. Rakshi JS, Uema T, Ito K, Bailey DL, Morrish PK, Ashburner J, Dagher A, Jenkins IH, Friston KJ, Brooks DJ. 1999. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET study. Brain 122:1637-1650.
18. Shprintzen R. 2005. Velo-cardio-facial syndrome. In: Cassidy SB, Allanson JE, editors. Management of genetic syndromes, 2nd edition. New York: Wiley-Liss. pp 615-631.
19. Taba P, Asser T. 2002. Prevalence of Parkinson's disease in Estonia. Acta Neurol Scand 106:276-281.
20. Tam K, Bassett A, Chow E. 2004. The co-occurrence of 22q11 deletion syndrome and Parkinson disease: A new neurological feature? American Society of Human Genetics Meeting, Toronto, 2004. Available at: http://www.ashg.org/ genetics/abstracts/abs04/f769.htm (accessed August 7, 2008).
21. Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, Nelson LM. 2003. Incidence of Parkinson's disease: Variation by age, gender, and race/ethnicity. Am J Epidemiol 157:1015-1022.
22. Williams-Gray CH, Hampshire A, Robbins TW, Owen AM, Barker RA. 2007. Catechol O-methyltransferase val158Met genotype influences frontoparietal activity during planning in patients with Parkinson's disease. J Neurosci 27:4832-4838.
23. Wilson DI, Cross IE, Wren C, Scambler PJ, Burn J, Goodship J. 1994. Minimum prevalence of chromosome 22q11 deletions. Am J Hum Genet 55:A169.